VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On July 27, 2017, VBI Vaccines Inc. (the “Company”) will host a conference call and webcast to discuss interim data from a Phase 1 study of its preventative CMV vaccine. A copy of the conference call presentation materials is furnished hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit 99.1, hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed “filed” with the U.S. Securities and Exchange Commission nor incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 8.01 Other Events.
On July 27, 2017, the Company issued a press release announcing interim data from the Phase 1 study of its preventative CMV vaccine. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1* | July 27, 2017 Conference Call Presentation Materials | |
| 99.2 | Press Release dated July 27, 2017 |
* Furnished herewith
VBI Vaccines Inc/BC Exhibit…To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
